These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 24804697)

  • 1. A randomized trial of a home system to reduce nocturnal hypoglycemia in type 1 diabetes.
    Maahs DM; Calhoun P; Buckingham BA; Chase HP; Hramiak I; Lum J; Cameron F; Bequette BW; Aye T; Paul T; Slover R; Wadwa RP; Wilson DM; Kollman C; Beck RW;
    Diabetes Care; 2014 Jul; 37(7):1885-91. PubMed ID: 24804697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outpatient safety assessment of an in-home predictive low-glucose suspend system with type 1 diabetes subjects at elevated risk of nocturnal hypoglycemia.
    Buckingham BA; Cameron F; Calhoun P; Maahs DM; Wilson DM; Chase HP; Bequette BW; Lum J; Sibayan J; Beck RW; Kollman C
    Diabetes Technol Ther; 2013 Aug; 15(8):622-7. PubMed ID: 23883408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive Low-Glucose Insulin Suspension Reduces Duration of Nocturnal Hypoglycemia in Children Without Increasing Ketosis.
    Buckingham BA; Raghinaru D; Cameron F; Bequette BW; Chase HP; Maahs DM; Slover R; Wadwa RP; Wilson DM; Ly T; Aye T; Hramiak I; Clarson C; Stein R; Gallego PH; Lum J; Sibayan J; Kollman C; Beck RW;
    Diabetes Care; 2015 Jul; 38(7):1197-204. PubMed ID: 26049549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial.
    Forlenza GP; Li Z; Buckingham BA; Pinsker JE; Cengiz E; Wadwa RP; Ekhlaspour L; Church MM; Weinzimer SA; Jost E; Marcal T; Andre C; Carria L; Swanson V; Lum JW; Kollman C; Woodall W; Beck RW
    Diabetes Care; 2018 Oct; 41(10):2155-2161. PubMed ID: 30089663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive Hyperglycemia and Hypoglycemia Minimization: In-Home Evaluation of Safety, Feasibility, and Efficacy in Overnight Glucose Control in Type 1 Diabetes.
    Spaic T; Driscoll M; Raghinaru D; Buckingham BA; Wilson DM; Clinton P; Chase HP; Maahs DM; Forlenza GP; Jost E; Hramiak I; Paul T; Bequette BW; Cameron F; Beck RW; Kollman C; Lum JW; Ly TT;
    Diabetes Care; 2017 Mar; 40(3):359-366. PubMed ID: 28100606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of an Overnight Predictive Low-Glucose Suspend System in Relation to Hypoglycemia Risk Factors in Youth and Adults With Type 1 Diabetes.
    Calhoun PM; Buckingham BA; Maahs DM; Hramiak I; Wilson DM; Aye T; Clinton P; Chase P; Messer L; Kollman C; Beck RW; Lum J;
    J Diabetes Sci Technol; 2016 Nov; 10(6):1216-1221. PubMed ID: 27207890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of morning ketosis after overnight insulin suspension using an automated nocturnal predictive low glucose suspend system.
    Beck RW; Raghinaru D; Wadwa RP; Chase HP; Maahs DM; Buckingham BA;
    Diabetes Care; 2014; 37(5):1224-9. PubMed ID: 24757229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overnight closed-loop insulin delivery with model predictive control: assessment of hypoglycemia and hyperglycemia risk using simulation studies.
    Wilinska ME; Budiman ES; Taub MB; Elleri D; Allen JM; Acerini CL; Dunger DB; Hovorka R
    J Diabetes Sci Technol; 2009 Sep; 3(5):1109-20. PubMed ID: 20144424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-Clinic Evaluation of the MiniMed 670G System "Suspend Before Low" Feature in Children with Type 1 Diabetes.
    Wood MA; Shulman DI; Forlenza GP; Bode BW; Pinhas-Hamiel O; Buckingham BA; Kaiserman KB; Liljenquist DR; Bailey TS; Shin J; Huang S; Chen X; Cordero TL; Lee SW; Kaufman FR
    Diabetes Technol Ther; 2018 Nov; 20(11):731-737. PubMed ID: 30299976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MD-Logic overnight control for 6 weeks of home use in patients with type 1 diabetes: randomized crossover trial.
    Nimri R; Muller I; Atlas E; Miller S; Fogel A; Bratina N; Kordonouri O; Battelino T; Danne T; Phillip M
    Diabetes Care; 2014 Nov; 37(11):3025-32. PubMed ID: 25078901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged nocturnal hypoglycemia is common during 12 months of continuous glucose monitoring in children and adults with type 1 diabetes.
    Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group
    Diabetes Care; 2010 May; 33(5):1004-8. PubMed ID: 20200306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of nighttime 2-hour suspension of Basal insulin in pump-treated type 1 diabetes even in the absence of low glucose.
    Sherr JL; Palau Collazo M; Cengiz E; Michaud C; Carria L; Steffen AT; Weyman K; Zgorski M; Tichy E; Tamborlane WV; Weinzimer SA
    Diabetes Care; 2014; 37(3):773-9. PubMed ID: 24170766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Threshold-based insulin-pump interruption for reduction of hypoglycemia.
    Bergenstal RM; Klonoff DC; Garg SK; Bode BW; Meredith M; Slover RH; Ahmann AJ; Welsh JB; Lee SW; Kaufman FR;
    N Engl J Med; 2013 Jul; 369(3):224-32. PubMed ID: 23789889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The "Glucositter" overnight automated closed loop system for type 1 diabetes: a randomized crossover trial.
    Nimri R; Danne T; Kordonouri O; Atlas E; Bratina N; Biester T; Avbelj M; Miller S; Muller I; Phillip M; Battelino T
    Pediatr Diabetes; 2013 May; 14(3):159-67. PubMed ID: 23448393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overnight closed-loop insulin delivery in young people with type 1 diabetes: a free-living, randomized clinical trial.
    Hovorka R; Elleri D; Thabit H; Allen JM; Leelarathna L; El-Khairi R; Kumareswaran K; Caldwell K; Calhoun P; Kollman C; Murphy HR; Acerini CL; Wilinska ME; Nodale M; Dunger DB
    Diabetes Care; 2014; 37(5):1204-11. PubMed ID: 24757227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension.
    Buckingham B; Chase HP; Dassau E; Cobry E; Clinton P; Gage V; Caswell K; Wilkinson J; Cameron F; Lee H; Bequette BW; Doyle FJ
    Diabetes Care; 2010 May; 33(5):1013-7. PubMed ID: 20200307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of a Predictive Algorithm in the Prevention of Exercise-Induced Hypoglycemia in Type 1 Diabetes.
    Abraham MB; Davey R; O'Grady MJ; Ly TT; Paramalingam N; Fournier PA; Roy A; Grosman B; Kurtz N; Fairchild JM; King BR; Ambler GR; Cameron F; Jones TW; Davis EA
    Diabetes Technol Ther; 2016 Sep; 18(9):543-50. PubMed ID: 27505305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of MiniMed 640G Insulin Pump with SmartGuard in Prevention of Low Glucose Events in Adults with Type 1 Diabetes (SMILE): Design of a Hypoglycemia Prevention Trial with Continuous Glucose Monitoring Data as Outcomes.
    De Valk HW; Lablanche S; Bosi E; Choudhary P; Silva JD; Castaneda J; Vorrink L; De Portu S; Cohen O
    Diabetes Technol Ther; 2018 Nov; 20(11):758-766. PubMed ID: 30325656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Let the Algorithm Do the Work": Reduction of Hypoglycemia Using Sensor-Augmented Pump Therapy with Predictive Insulin Suspension (SmartGuard) in Pediatric Type 1 Diabetes Patients.
    Biester T; Kordonouri O; Holder M; Remus K; Kieninger-Baum D; Wadien T; Danne T
    Diabetes Technol Ther; 2017 Mar; 19(3):173-182. PubMed ID: 28099035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity of the Predictive Hypoglycemia Minimizer System to the Algorithm Aggressiveness Factor.
    Finan DA; Dassau E; Breton MD; Patek SD; McCann TW; Kovatchev BP; Doyle FJ; Levy BL; Venugopalan R
    J Diabetes Sci Technol; 2015 Jun; 10(1):104-10. PubMed ID: 26134834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.